Telix Issues US$550M Convertible Bonds with 1.5–1.75% Coupon
Telix launches a US$550 million convertible note offering due 2031 guaranteed by its parent entities, with a 1.50–1.75% coupon and 35–37.5% conversion premium to current share price. Net proceeds will repurchase outstanding 2029 bonds, with any surplus funding general corporate purposes.
1. Convertible Bond Offering
Telix Pharmaceuticals’ wholly-owned subsidiary will issue US$550 million in convertible notes due 2031, guaranteed by Telix and its US unit. The bonds carry a coupon of 1.50–1.75% and convert at a 35–37.5% premium to the clearing price from a concurrent delta placement.
2. Use of Proceeds
After commissions and fees, net proceeds are earmarked to repurchase outstanding convertible bonds due 2029 via a reverse bookbuilding process, with any excess funds allocated to general corporate purposes, enhancing Telix’s capital structure.
3. Conversion and Hedging Arrangements
A delta placement will establish the reference share price used to set the initial conversion price, and a stock lending facility with an affiliate of J.P. Morgan will support investors’ hedging activities in relation to the convertible bonds.
4. Concurrent Repurchase Process
Telix is conducting a reverse bookbuild to gauge interest from holders of existing bonds on a repurchase offer, with J.P. Morgan acting as sole bookrunner for the new issuance and dealer manager for the repurchase.